MaxCyte Q2 2024 GAAP EPS $(0.09) Beats $(0.12) Estimate, Sales $10.429M Beat $7.923M Estimate
Portfolio Pulse from Benzinga Newsdesk
MaxCyte (NASDAQ:MXCT) reported Q2 2024 GAAP EPS of $(0.09), beating the $(0.12) estimate. Sales were $10.429M, surpassing the $7.923M estimate and showing a 15.33% increase from last year's $9.043M.
August 06, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MaxCyte reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.09) beating the $(0.12) estimate and sales of $10.429M surpassing the $7.923M estimate. Sales increased by 15.33% YoY.
The better-than-expected earnings and sales figures are likely to positively impact MaxCyte's stock price in the short term. Beating both EPS and sales estimates by significant margins indicates strong performance and growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100